# STAT News Type: Company Source: GetYourBrief — https://getyourbrief.com/entity/stat-news-company Canonical HTML page: https://getyourbrief.com/entity/stat-news-company ## Timeline - **2027-Q1**: Expected FDA submission — Lilly plans to file retatrutide for FDA approval. - **2026-09-13**: State and local death toll diverges from CDC — As of Sunday, state and local officials had reported three measles-related deaths, a figure that did not square with CDC data, highlighting a surveillance or reporting discrepancy. - **2026-09-12**: Third measles-related death reported — A 40-year-old Jefferson County woman died from complications associated with measles, according to Jefferson County Coroner Greg Furlong. Her vaccination status was not disclosed. - **2026-09-11**: Pennsylvania reports 676 measles cases — The state health department counted 676 measles cases across 37 counties, 124 hospitalizations, and 4 cases among vaccinated individuals as of Friday. - **2026-09-09**: Coroner releases death details — Lancaster County Coroner Stephen Diamantoni confirmed details to the CDC and public, saying he reported his conclusions to the CDC in response to a state right-to-know request. - **2026-08-19T20:15:00Z**: Hartford Courant reports Trump picks Overton — The Hartford Courant reports Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA. - **2026-08-19T20:15:00Z**: Hartford Courant reports Trump picks Overton — The Hartford Courant reports Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA. - **2026-08-19T20:00:00Z**: ABC7 News reports Trump picks Overton — ABC7 News publishes a headline stating Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA. - **2026-08-19T20:00:00Z**: ABC7 News reports Trump picks Overton — ABC7 News publishes a headline stating Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA. - **2026-08-19T01:18:25Z**: STAT News reports Trump expected to pick Overton — STAT reports that President Trump is expected to choose White House adviser and physician Heidi Overton to lead the Food and Drug Administration. - **2026-08-19T01:18:25Z**: STAT News reports Trump expected to pick Overton — STAT reports that President Trump is expected to choose White House adviser and physician Heidi Overton to lead the Food and Drug Administration. - **2026-08-18**: Mary Stoltzfus dies at 6 weeks old — Mary Stoltzfus died at home. She had Amish lethal microcephaly and a measles infection killed her, the coroner told the Associated Press. - **2026-08-14**: Ivan Miller dies shortly after birth — Ivan Miller died from a ruptured spleen. Measles was listed on the death certificate as a contributing factor but did not cause the spleen rupture, according to Coroner Stephen Diamantoni. - **2026-08-03**: Early access program announced — Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval. - **2026-08**: Two measles-related infant deaths reported — A newborn boy died shortly after birth from a ruptured spleen, with measles listed as a significant condition but not the cause, and a 6-week-old girl with Amish lethal microcephaly died due to measles. Both infants were too young for the first measles vaccine dose. ## Recent coverage (8 stories, network-wide) ### PA's 3rd Measles Death: 676 Cases, 124 Hospitalized in 2026 2026-09-14 15:49:01 · Sector: health · Sentiment: Strongly negative · Impact: 6/10 · Sources: 2 A third measles-related death in Pennsylvania—a 40-year-old woman—signals a widening outbreak with 676 cases across 37 counties and 124 hospitalizations. Health systems and public health agencies now face both infant and adult severe cases, with vaccination status and federal-state data discrepancies adding complexity. Full story: https://gethealthbrief.com/story/pa-third-measles-death-676-cases-124-hospitalized ### Measles Outbreak: Coroner Cites Virus in 1 of 2 PA Infant Deaths 2026-09-10 17:05:28 · Sector: health · Sentiment: Strongly negative · Impact: 6/10 · Sources: 2 Pennsylvania's coroner confirms measles directly killed a 6-week-old with a fatal genetic disorder, while a newborn's death was due to a ruptured spleen, not the virus. The distinctions carry major weight for CDC classification and outbreak response. Full story: https://gethealthbrief.com/story/measles-pa-infant-deaths-coroner-health ### Heidi Overton FDA pick: 3 regulatory areas health IT should watch 2026-08-19 21:12:01 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 3 Reports that Dr. Heidi Overton will be nominated to lead FDA introduce new regulatory uncertainty for health IT vendors, medical device manufacturers, and digital health companies. As a White House adviser without a public FDA track record, her stance on software-as-a-medical-device, telehealth, and AI-enabled diagnostics is unclear. Health technology leaders should monitor confirmation and early policy signals. Full story: https://gethealthbrief.com/story/overton-fda-health-it-regulatory-watch ### Overton FDA pick: 3 drug approval questions biotech must watch 2026-08-19 21:11:52 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 3 Biotech and pharma investors and executives face a potentially new FDA commissioner with no public drug-review track record. If Dr. Heidi Overton is confirmed, her priorities could reshape clinical trial standards, accelerated approval pathways, and review timelines. Early signals from the White House and confirmation hearings will matter most. Full story: https://getbiobrief.com/story/overton-fda-biotech-approval-questions ### Eli Lilly’s retatrutide EAP: access for patients with 2+ severe comorbidities 2026-08-05 10:24:43 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2 Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence. Full story: https://gethealthbrief.com/story/eli-lilly-retatrutide-expanded-access-obesity-drug-2026 ### Bullish Options Surge in Sarepta Therapeutics Amid Promising Rare Disease Data 2026-03-25 19:55:52 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Traders have flooded Sarepta Therapeutics with call options following positive early-stage data for its RNA-based rare disease therapies. This surge in bullish sentiment suggests high market confidence in the company's clinical pipeline expansion beyond its core Duchenne muscular dystrophy franchise. Full story: https://getfinancebrief.com/story/sarepta-therapeutics-options-volume-surge-2026 ### Big Pharma’s Antibiotic Pipeline Shrinks 35% as Market Failures Deepen 2026-03-10 11:45:16 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2 A new analysis reveals a 35% decline in antimicrobial R&D by major pharmaceutical companies over the last five years, highlighting a deepening crisis in the fight against drug-resistant superbugs. The exodus of large-scale investment underscores the persistent lack of economic incentives for developing life-saving antibiotics. Full story: https://getbiobrief.com/story/big-pharma-antibiotic-pipeline-decline-analysis ### Big Pharma Antibiotic Pipelines Nosedive 35% as Market Challenges Persist 2026-03-10 11:43:38 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 2 A new analysis reveals a 35% decline in antimicrobial R&D among the world's largest pharmaceutical companies over the last five years. This retreat highlights a deepening crisis in the antibiotic market, where low returns on investment are driving major players toward more lucrative therapeutic areas. Full story: https://gethealthbrief.com/story/big-pharma-antibiotic-pipeline-decline-analysis --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.